Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of EML4-ALK Lung Cancer

被引：0
|
作者：
Arai, S. [1 ]
Takeuchi, S. [1 ]
Fukuda, K. [1 ]
Nishiyama, A. [1 ]
Tanimoto, A. [1 ]
Taniguchi, H. [1 ]
Satouchi, M. [2 ]
Nanjo, S. [1 ]
Katayama, R. [3 ]
Nishio, M. [4 ]
Zheng, M. [5 ]
Wu, Y. [6 ,7 ]
Yano, S. [1 ]
机构：
[1] Kanazawa Univ, Canc Res Inst, Kanazawa, Ishikawa, Japan
[2] Hyogo Canc Ctr, Akashi, Hyogo, Japan
[3] Japanese Fdn Canc Res, Canc Chemotherapy Ctr, Tokyo, Japan
[4] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[5] Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[6] Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[7] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
leptomeningeal carcinomatosis; alectinib resistance; Osimertinib;
D O I：
10.1016/j.jtho.2019.08.1841
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.14-56
引用
收藏
页码：S852 / S853
页数：2
相关论文
共 50 条
  • [1] Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer
    Arai, Sachiko
    Takeuchi, Shinji
    Fukuda, Koji
    Taniguchi, Hirokazu
    Nishiyama, Akihiro
    Tanimoto, Azusa
    Satouchi, Miyako
    Yamashita, Kaname
    Ohtsubo, Koshiro
    Nanjo, Shigeki
    Kumagai, Toru
    Katayama, Ryohei
    Nishio, Makoto
    Zheng, Mei-mei
    Wu, Yi-Long
    Nishihara, Hiroshi
    Yamamoto, Takushi
    Nakada, Mitsutoshi
    Yano, Seiji
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (05) : 752 - 765
  • [2] Mechanisms of Alectinib Resistance in a Leptomeningeal Carcinomatosis of EML4-ALK Lung Cancer and Its Circumvention by EGR-TKIs
    Yano, S.
    Arai, S.
    Fukuda, K.
    Takeuchi, S.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) : S29 - S29
  • [3] ALK inactivation induced acquired resistance to alectinib in lung cancer harboring EML4-ALK fusion gene
    Isozaki, Hideko
    Ichihara, Eiki
    Yasugi, Masayuki
    Nobuaki, Ochi
    Hotta, Katsuyuki
    Takigawa, Nagio
    Sendo, Toshiaki
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    CANCER RESEARCH, 2014, 74 (19)
  • [4] EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature
    Batra, Ullas
    Sharma, Mansi
    Amrith, B. P.
    Mehta, Anurag
    Jain, Parveen
    CLINICAL LUNG CANCER, 2020, 21 (06) : E597 - E600
  • [5] Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance
    Liu, Di
    Xu, Xinyan
    Wen, Junmiao
    Zhang, Chi
    Fan, Min
    LUNG CANCER, 2021, 160 : 32 - 35
  • [6] EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
    Choi, Young Lim
    Soda, Manabu
    Yamashita, Yoshihiro
    Ueno, Toshihide
    Takashima, Junpei
    Nakajima, Takahiro
    Yatabe, Yasushi
    Takeuchi, Kengo
    Hamada, Toru
    Haruta, Hidenori
    Ishikawa, Yuichi
    Kimura, Hideki
    Mitsudomi, Tetsuya
    Tanio, Yoshiro
    Mano, Hiroyuki
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18): : 1734 - 1739
  • [7] Amphiregulin confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by EGFR inhibitors
    Taniguchi, Hirokazu
    Takeuchi, Shinji
    Fukuda, Koji
    Nakagawa, Takayuki
    Arai, Sachiko
    Nanjo, Shigeki
    Yamada, Tadaaki
    Yamaguchi, Hiroyuki
    Mukae, Hiroshi
    Yano, Seiji
    CANCER SCIENCE, 2018, 109 : 736 - 736
  • [8] EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report
    von Buttlar, Xinyu
    Reuss, Joshua E.
    V. Liu, Stephen
    Kim, Chul
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (06):
  • [9] Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity
    Emily K. Kleczko
    Trista K. Hinz
    Teresa T. Nguyen
    Natalia J. Gurule
    Andre Navarro
    Anh T. Le
    Amber M. Johnson
    Jeff Kwak
    Diana I. Polhac
    Eric T. Clambey
    Mary Weiser-Evans
    Daniel T. Merrick
    Michael C. Yang
    Tejas Patil
    Erin L. Schenk
    Lynn E. Heasley
    Raphael A. Nemenoff
    npj Precision Oncology, 7
  • [10] EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer
    Hui, Beina
    Zhang, Jingping
    Shi, Xiaobo
    Xing, Fangfang
    Shao, Yang W.
    Wang, Yuanyuan
    Zhang, Xiaozhi
    Wang, Shuwen
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (12) : 1470 - 1474
12345